Oxford Biomedica plc (LON:OXB - Get Free Report)'s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 339.58 ($4.64) and traded as low as GBX 308 ($4.21). Oxford Biomedica shares last traded at GBX 320 ($4.37), with a volume of 149,774 shares.
Oxford Biomedica Stock Performance
The firm has a market cap of £355.58 million, a price-to-earnings ratio of -2.49 and a beta of 1.09. The stock's fifty day moving average is GBX 313.20 and its two-hundred day moving average is GBX 338.91. The company has a debt-to-equity ratio of 166.48, a quick ratio of 1.67 and a current ratio of 2.35.
Oxford Biomedica (LON:OXB - Get Free Report) last announced its quarterly earnings results on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.57)) EPS for the quarter. Oxford Biomedica had a negative net margin of 145.98% and a negative return on equity of 202.50%. On average, analysts expect that Oxford Biomedica plc will post -31.0799998 earnings per share for the current fiscal year.
Insider Activity at Oxford Biomedica
In related news, insider Heather Preston purchased 11,389 shares of the company's stock in a transaction on Tuesday, June 17th. The shares were bought at an average cost of GBX 324 ($4.42) per share, for a total transaction of £36,900.36 ($50,389.68). Company insiders own 21.17% of the company's stock.
About Oxford Biomedica
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Read More
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
